Article Versions Notes

Li Y-C, Shih Y-H, Chen T-C, Gau J-P, Su Y-C, Chen M-H, Hsu C-Y, Liao C-S, Teng C-LJ. Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia. Journal of Clinical Medicine. 2021; 10(24):5768. https://doi.org/10.3390/jcm10245768

Li, You-Cheng, Yu-Hsuan Shih, Tsung-Chih Chen, Jyh-Pyng Gau, Yu-Chen Su, Mei-Hui Chen, Chiann-Yi Hsu, Cai-Sian Liao, and Chieh-Lin Jerry Teng. 2021. "Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia" Journal of Clinical Medicine 10, no. 24: 5768. https://doi.org/10.3390/jcm10245768

Li, Y.-C., Shih, Y.-H., Chen, T.-C., Gau, J.-P., Su, Y.-C., Chen, M.-H., Hsu, C.-Y., Liao, C.-S., & Teng, C.-L. J. (2021). Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia. Journal of Clinical Medicine, 10(24), 5768. https://doi.org/10.3390/jcm10245768